Russell Alan J - Sep 20, 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Scientific Officer, Director
Signature
/s/ John R. Moore, Attorney-in-Fact for Russell Alan J
Stock symbol
EWTX
Transactions as of
Sep 20, 2024
Transactions value $
-$2,106,601
Form type
4
Date filed
9/24/2024, 08:25 PM
Previous filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $13.5K +75K +589.67% $0.18 87.7K Sep 20, 2024 Direct F1
transaction EWTX Common Stock Sale -$2.1M -74.2K -84.57% $28.25 13.5K Sep 20, 2024 Direct F2
transaction EWTX Common Stock Sale -$24K -815 -6.02% $29.51 12.7K Sep 20, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -75K -4.9% $0.00 1.46M Sep 20, 2024 Common Stock 75K $0.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,968 shares purchased on May 15, 2023, 2,088 shares purchased on November 15, 2023 and 425 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $28.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.56, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/48th of the shares subject to the option vested each month beginning on June 27, 2017.